Kyverna steps closer to FDA-first CAR T for an autoimmune condition with durability data

Kyverna Therapeutics' miv-cel showed improved mobility and a favorable safety profile at one year in patients with stiff person syndrome, further derisking an upcoming FDA application, William Blair said on Thursday. The biotech plans to file for priority review this year.